Ardena Names Dr. Ariane de Ganck as Chief Scientific Officer

Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO, has appointed Ariane de Ganck, PhD, as Chief Scientific Officer (CSO).

De Ganck will help ensure Ardena’s scientific expertise is effectively aligned across services and sites, so complex drug development programs benefit from coordinated technical insight, consistent project execution and robust regulatory strategy.

As Chief Scientific Officer, she will lead three key areas:

• Science & Technology
• Project Management
• CMC Regulatory Affairs

“Ariane’s track record across scientific, operational and commercial leadership roles makes her exceptionally well suited to this position,” said Jeremie Trochu, CEO of Ardena. “For customers developing complex molecules, integrated scientific input across disciplines is essential. As Chief Scientific Officer, Ariane will help ensure Ardena’s expertise is applied consistently across complex development programs, supporting our customers as they advance therapies with the potential to improve patients’ lives.”

Earlier this year, Ardena also named a new Chief Financial Officer and Chief Commercial Officer.

Experience

De Ganck brings a strong track record within Ardena, including her leadership of the company’s Drug Product division since 2022 and her recent role as Chief Commercial Officer. Since joining Ardena in 2019, she has overseen the company’s drug product operations, led the successful acquisition and integration of the Ardena Pamplona site, and supported the expansion of Ardena’s development capabilities into aseptic fill and finish services.

De Ganck’s senior management experience spans the CRO and CDMO sectors, with expertise across drug product development, CMC regulatory affairs, biomarkers and laboratory services. Prior to joining Ardena, she worked at Biogazelle, a specialist CRO in biomarker discovery and diagnostics, until its successful sale to CellCarta.

De Ganck holds a PhD in Biomedical Sciences, with a specialty in oncology and protein biology.

“Scientific expertise is the foundation of how Ardena supports complex drug development, from drug substance and drug product through to bioanalysis, nanomedicines, solid-state chemistry and CMC regulatory services,” said de Ganck. “I am honored and excited to take on this role and work with our teams to build on that foundation, foster scientific exchange and support the continued application of Ardena’s knowledge across complex development programs.”